SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽Demo🎬Demo VideoℹVision

What is the mechanistic link between SMPD1 inhibition, ceramide depletion, and EGFR signaling disruption in GBM?

OPEN

The abstract identifies SMPD1 as regulating sphingomyelin-to-ceramide conversion and shows fluoxetine inhibits EGFR signaling, but the molecular pathway connecting these events is unclear. This mechanistic gap limits rational drug design and combination strategies. Gap type: unexplained_observation Source paper: Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. (None, None, PMID:34731610)

Priority: 0.83 Domain: neuro-oncology Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: What is the mechanistic link between SMPD1 inhibition, ceramide depletion, and EGFR signaling disruption in GBM? is a 0.83 priority gap in neuro-oncology. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What is the mechanistic link between SMPD1 inhibition, ceramide depletion, and EGFR signaling disruption in GBM? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (16)

EGFR→Egfr SignalingEGFR→CANCERAPOPTOSIS→EGFREGFR→AKTEGFR→Cancer
▸ Show 11 more

data in (4)

benchmark_ot_ad_answer_key:EGFR→EGFREGFR→benchmark_ot_ad_answer_key:EGFRbenchmark_ot_ad_answer_key:SMPD1→SMPD1SMPD1→benchmark_ot_ad_answer_key:SMPD1

encodes (1)

EGFR→EGFR

expressed in (1)

EGFR→Tumor

inhibits (6)

EGFR→CancerEGFR→TumorEGFR→Lung CancerCANCER→EGFREGFR→Als
▸ Show 1 more

targets (2)

EGFR→tyrosine kinase inhibitorsEGFR→monoclonal antibodies

therapeutic target (20)

EGFR→Drug ResistanceGBM→GLIOBLASTOMAEGFR→Pi3K/AktEGFR→Lung CancerEGFR→Breast Cancer
▸ Show 15 more
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps